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Abstract
In a retrospective study, Dr Muller and colleagues have assessed
the efficacy of mupirocin nasal ointment alongside hygienic
measures in methicillin-resistant Staphylococcus aureus (MRSA)-
positive patients admitted to the intensive care unit (ICU). Their
findings, which suggest that intranasal mupirocin can prevent ICU-
related MRSA infections, need confirmation in a well-designed
clinical trial. In general: early identification, isolation and treatment
of all MRSA carriers, including health care workers, and dis-
infection of contaminated environments, are the main ‘ingredients’
of an effective MRSA ‘search and destroy’ program.
In this issue of Critical Care, AA Muller and colleagues
present a study in which they assessed the efficacy of
mupirocin nasal ointment in preventing methicillin-resistant
Staphylococcus aureus (MRSA) infections in an intensive care
unit (ICU) [1]. MRSA constitutes a special problem with
regard to the prevention and treatment of infection. Studies
show that MRSA carriers have a higher risk of nosocomial
infection with this microorganism, and that those infected with
MRSA have a greater morbidity and mortality than those
infected with susceptible strains [2,3]. It is therefore important
to keep the prevalence of MRSA carriage and MRSA
infections low. Efforts to achieve this should be supported.
Muller and colleagues performed a retrospective study in
which they compared a 2-year MRSA control program with
intranasal application of mupirocin, with a 2-year program in
which mupirocin was not used. The MRSA control program
consisted of screening for MRSA carriage at admission, and,
in the event of MRSA carriage, hygienic measures to prevent
cross-transmission were intensified. This study is clinically
relevant, but the study design used is very susceptible to
many biases and their results should therefore be interpreted
with caution. Their findings, which suggest that intranasal
mupirocin can prevent ICU-related MRSA infections, need
confirmation in a well-designed clinical trial.
Results from recent clinical trials that studied the efficacy of
mupirocin nasal ointment in preventing methicillin-susceptible
S. aureus (MSSA) infections can be extrapolated to MRSA
infections. MSSA and MRSA are essentially the same
microorganism, except that the latter is more difficult to treat
with antibiotics. Several double-blind randomized placebo-
controlled trials with mupirocin nasal ointment have been
performed in both surgical and non-surgical patients, with
S. aureus infection as the outcome measurement [4-7]. The
results of these trials have been disappointing. So far, there is
only evidence that mupirocin is beneficial for dialysis patients
and general surgery patients [4,7]. But can mupirocin nasal
ointment prevent MRSA infections in ICUs?
In comparison with non-ICU patients, critically ill patients
admitted to ICUs may receive more benefit from mupirocin,
even when moderately efficacious, because the rate of S.
aureus infections in ICU patients is much higher. Corbella
and colleagues reported a relative risk of acquiring
nosocomial S. aureus bacteremia of 59.6 (95% confidence
interval 20.4 to 184.3) for nasal carriers after 14 days of ICU
stay, compared with non-carriers [8]. Another study found a
relative risk for S. aureus bacteremia of 3.9 (95% confidence
interval 1.6 to 9.8) for MRSA carriers compared with MSSA
carriers [2]. These risk estimates in ICUs are significantly
higher than a recently reported threefold increased risk for S.
aureus nasal carriers of acquiring nosocomial S. aureus
bacteremia in a general hospital population [9]. Although the
clinical trials described above may not be extrapolated to a
high-risk setting, they do warn us not to have too high
expectations of this drug.
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Muller and colleagues also report the use of other preventive
measures in the event of MRSA carriage. The extra hygienic
precautions they implemented for this should, in our view, be
standard care for any patient admitted to an ICU, irrespective
of MRSA carriage. Currently there is a debate about whether
infection control policies in an ICU can prevent cross-
transmission of MRSA [10,11]. However, history teaches us
that MRSA prevalence is still low in countries where strict
infection control policies were implemented soon after the
first MRSA strains were detected [12]. These policies also
include health care workers and the environment, besides
patients, as potential reservoirs of MRSA. Early identification,
isolation and treatment of all MRSA carriers, including health
care workers, and disinfection of contaminated environments
are the main ‘ingredients’ of an effective ‘search and destroy’
program. The current study focuses only on the eradication of
MRSA from colonized patients, which is just one part of an
effective MRSA control program.
Since 2002, the first three vancomycin-resistant MRSA
strains have been isolated in the USA [13-15]. Preventing the
spread of MRSA and preventing staphylococcal infections
are therefore essential. The high usage of vancomycin in
ICUs should alert us to the possibility of vancomycin-resistant
strains. Effective strategies that can prevent the spread of
MRSA and the development of MRSA infections still need to
be developed. The use of mupirocin nasal ointment alone will
not be sufficient. Increased usage of mupirocin in an MRSA
endemic situation, such as ICUs, will lead to the selection of
mupirocin-resistant strains [16]. This may hamper the
beneficial effects of mupirocin in other patient categories in
the long term. There is no evidence yet that mupirocin is
effective in preventing MRSA or MSSA infections in ICUs. An
international MRSA prevention task force should be set up,
with sufficient funding and expertise to develop the right
strategies and validate these strategies in clinical trials. We
still have a long way to go.
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